Overall verdict
Neutral
5.5/10
1-year performance
+46.95%
Score breakdown
Up 47.0% over 1 year, 100% of the 52-week range.
Strongest: Profitability 9.6/10. Weakest: Growth 2.1/10.
23 analysts, target -0.0% vs the price.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures ;
instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies ; breast aesthetics and reconstruction ; contact lenses under the ACUVUE brand ; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Nyse
United States
CEO
Joaquin Duato
Founded
1886
Employees
140 800
Revenue / employee
668 878 USD
Next earnings
January 19, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.72%
- Bank of New York Mellon Corp0.90%
- FMR LLC0.78%
- Rest of the register95.61%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
284.15 USD
52-week low
189.05 USD
1-year performance
46.95%
Rising
Year-to-date performance
37.39%
Rising
Drawdown
0.00%
Near its high
Position in the 52-week range
100% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned more, with as much risk: once that risk is counted, it did about as well as the ETF.
$10,000 placed at the end of December 2000 are worth today
| Johnson & Johnson | $102,627 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves about as much as the world ETF.
- Worst fall:-28 % between August 2008 and February 2009. $10,000 placed at the top fell to $7,218. The world ETF, at worst: -53 %. Back to its high in 26 months.
Johnson & Johnson earned more than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Johnson & Johnson: $102,627
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 155.42 USD - 179.82 USD (2 methods agree)
The price implies growth of 11.63% per year; the company grows at 14.90%.
Gross margin 67.6%, net margin 16.2%, ROIC 13.6%, ROE 20.0%.
Net margin
16.20%
Exceptional
Sector 9.96%|S&P 13.40%
Gross margin
67.65%
High
Return on equity (ROE)
20.02%
Exceptional
Sector 6.73%|S&P 17.06%
Return on invested capital (ROIC)
13.64%
Exceptional
Free cash flow margin (FCF)
20.73%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.28x
High
Margin stability
9.6 pts
Uneven
Revenue to net income
Growth
2.1/10Revenue up 5.9% over 1 year, 2.7% a year over 5, EPS 14.9% a year over 5.
Revenue (trailing 12 months)
99.3Md USD
Revenue growth (1y)
5.87%
Solid
Revenue growth (3y)
17.63%
Solid
EPS growth (1y)
-95.96%
Declining
EPS CAGR (5y)
14.90%
Exceptional
EPS revisions (3 months)
0.61%
Revised up
Valuation
2.1/10P/E 43.1x, forward P/E 41.6x, EV/EBITDA 21.0x, PEG 2.89. The multiple sits in the 79th percentile of its own 5-year history.
P/E (TTM)
43.1x
Expensive
Sector 27.7x|S&P 23.6x
Forward P/E
41.6x
Very expensive
EV / EBITDA
21.0x
Expensive
Sector 14.2x|S&P 15.5x
PEG
2.89
Very expensive
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
171.92 USD
Deeply overvalued
P/E vs its own 5-year history
among the 21% highest valuations
Pricier than usual
Market cap
684Md USD
Financial strength
8.7/10Cash covers 38.6% of the debt, net debt/EBITDA 0.9x.
Net debt / EBITDA
0.9x
Solid
Gearing (net debt / equity)
33.64%
Solid
Cash
17.2Md USD
Cash / market cap
2.52%
Stretched
Cash / total debt
38.58%
Solid
Interest coverage
22.1x
Very solid
Net debt
27.4Md USD
Equity
81.5Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 280.78 USD
- MM20267.20
- MM50266.37
- MM200248.94
- RSI 1462.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+2.35%
200-day average slope, 3 months
+8.67%
50-day average slope, 1 month
+0.33%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
1.62 % per day
Volatility change
+11.01%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 6.83 (4) | 11.12 (21) | 101 222 (21) | 35 985 (8) | 16 558 (3) |
| 2027 | 10.07 (5) | 11.62 (22) | 107 753 (21) | 38 344 (8) | 23 793 (3) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 9, 2026.
Same sub-industry: 503 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AZN | 7.1 | 7.0 | 286Md USD | 26.7x | 17.7 % | 7.1 % | 14.4 % | 1.2x | 3.6 % | 3.7 % | ||
| 2 | BMY | 6.6 | 6.9 | 129Md USD | 13.9x | 18.5 % | 7.0 % | 14.0 % | 1.9x | 7.2 % | 32.5 % | ||
| 3 | NOVO B | 6.2 | 7.7 | 178Md USD | 10.7x | 33.9 % | 5.6 % | 38.1 % | 0.7x | 6.0 % | -8.5 % | ||
| 4 | ROP | 6.2 | 6.4 | 385Md USD | 26.2x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 4.7 % | 42.5 % | ||
| 5 | NOVN | 6.1 | 6.5 | 295Md USD | 32.0x | 18.0 % | 6.0 % | 13.5 % | 1.0x | 5.0 % | 29.2 % | ||
| 6 | LLY | 6.0 | 5.1 | 1.4T USD | 47.2x | 31.9 % | 38.6 % | 36.3 % | 1.2x | 1.5 % | 48.7 % | ||
| 7 | JNJ | 5.5 | 5.2 | 684Md USD | 43.1x | 16.2 % | 5.9 % | 13.6 % | 0.9x | 3.0 % | 47.0 % | ||
| 8 | MRK | 5.4 | 3.6 | 363Md USD | 150.3x | 3.6 % | 5.5 % | 2.6 % | 1.2x | 4.1 % | 68.5 % | ||
| 9 | PFE | 5.2 | 4.6 | 168Md USD | 42.1x | 6.3 % | -0.4 % | 2.7 % | 2.3x | 7.0 % | 20.3 % |
